china: China’s neglected generic-drugs industry is looking up. Can it become as significant as India’s?
2 years ago
[ad_1]
A worker checks the position of a feeding tray in a pharmaceutical manufacturing truck at the Hengrui Biomedical Industrial Park in East China’s Jiangsu province, December 13, 2021.
Synopsis
After years of development, China’s generic-drugs industry has matured, especially after regulators adopted a “consistency evaluation” system to ensure that the quality and efficacy of generics are equivalent to those of brand-name drugs. Earlier neglected because of slimmer investment returns, this segment is now attracting attention, with the potential to explore markets beyond its boundaries.
Chinese drugmaker Jiangsu Hengrui Pharmaceuticals Co. Ltd. won U.S. regulatory approval in May to market its iodixanol injection for cancer, bringing a long-overdue buzz to China’s silent generic drug industry.Over the past few years, innovative drug development has been vigorously promoted with capital and policies in China. Meanwhile, the generic drug industry has been shrinking due to strict price controls under China’s national drug
BY
Caixin Global
Gift A Story
Share member-only stories with your friends or family and help them read it for free.
Gifting Limit Reached!
Hey , no more stories left for you to gift.
No worries! You will get a limit of 15 stories next month to share with your friends and family.
Gift This Story
Stories Left!
You can gift upto 15 stories in a month.
FONT SIZE
AbcSmall
AbcMedium
AbcLarge
SAVE
PRINT
COMMENT
Already an ET Prime Member? Sign In now
Continue reading with one of these options:
Limited Access
Free
Login to get access to some exclusive stories & personalised newsletters
Login Now
Unlimited Access
Starting @ Rs120/month
Get access to exclusive stories, expert opinions & in-depth stock reports
Subscribe Now
To read full story, subscribe to ET Prime
Get Unlimited Access to The Economic Times
₹34 per week
Billed annually at ₹2499 ₹1749
Already a Member? Sign In now
Sign in to read the full article
You’ve got this Prime Story as a Free Gift
Rs 49 for 1st month
Then Rs. 1,749 per year
SUBSCRIBE NOW
Valid only with UPI, Credit & Debit Cards Autopay
Choose Payment Mode & Plan
–
–
–
Subscribe Now
(Credit card mandatory)
You can cancel your subscription anytime
–
–
–
Subscribe Now
(Pay Using Netbanking/UPI/Debit Card)
Netbanking, Credit & Debit Card
Subscribe with Google
₹399/month
Monthly
PLAN
Billed Amount ₹399
₹399
₹208/month
(Save 49%)
Yearly
PLAN
Billed Amount ₹2,499
15
Days Trial +Includes DocuBay and TimesPrime Membership.
₹399
₹150/month
(Save 63%)
2-Year
PLAN
Billed Amount ₹3,599
15
Days Trial +Includes DocuBay and TimesPrime Membership.
Get ET Prime for just ₹2499 ₹1749/yr
Already a Member? Sign In now
Enjoy Additional Benefits as ET Prime Member
Now Save 63%
on 2 Year Membership
Explore Plans
Why ?
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
Clean experience with Minimal Ads
Comment & Engage with ET Prime community
Exclusive invites to Virtual Events with Industry Leaders
A trusted team of Journalists & Analysts who can best filter signal from noise